MediciNova Stock Price, News & Analysis (NASDAQ:MNOV)

$6.88 -0.01 (-0.15 %)
(As of 12/11/2017 01:51 PM ET)
Previous Close$6.89
Today's Range$6.86 - $7.20
52-Week Range$4.40 - $7.85
Volume165,400 shs
Average Volume65,935 shs
Market Capitalization$248.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04

About MediciNova (NASDAQ:MNOV)

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio14.46%
Quick Ratio14.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book6.88

Profitability

Trailing EPS($0.32)
Net Income$-10,860,000.00
Net MarginsN/A
Return on Equity-32.53%
Return on Assets-28.27%

Miscellaneous

Employees10
Outstanding Shares36,100,000

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.

Who are some of MediciNova's key competitors?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:

  • Jeffrey Himawan Ph.D., Independent Chairman of the Board (Age 52)
  • Yuichi Iwaki M.D., Ph.D., President, Chief Executive Officer, Director (Age 65)
  • Ryan Selhorn, Chief Financial Officer
  • Geoffrey G. O'Brien J.D., Vice President (Age 46)
  • Masatsune Okajima, Vice President, Head - Japanese Office (Age 47)
  • Kazuko Matsuda M.D., Ph.D., Chief Medical Officer (Age 48)
  • Hideki Nagao, Director (Age 61)
  • Yoshio Ishizaka, Independent Director (Age 75)
  • Yutaka Kobayashi, Independent Director (Age 51)

Who owns MediciNova stock?

MediciNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.10%), Wells Fargo & Company MN (0.09%) and Jane Street Group LLC (0.05%). Company insiders that own MediciNova stock include Geoffrey Obrien, Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.

Who sold MediciNova stock? Who is selling MediciNova stock?

MediciNova's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. View Insider Buying and Selling for MediciNova.

Who bought MediciNova stock? Who is buying MediciNova stock?

MediciNova's stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC and Wells Fargo & Company MN. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.

How do I buy MediciNova stock?

Shares of MediciNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MediciNova stock can currently be purchased for approximately $6.88.

How big of a company is MediciNova?

MediciNova has a market capitalization of $248.37 million. The biopharmaceutical company earns $-10,860,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. MediciNova employs 10 workers across the globe.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 650, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (MNOV)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MediciNova (NASDAQ:MNOV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$11.00$11.00
Price Target Upside: N/AN/A107.94% upside107.94% upside

MediciNova (NASDAQ:MNOV) Consensus Price Target History

Price Target History for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2017Credit Suisse GroupInitiated CoverageOutperform -> OutperformHighView Rating Details
3/21/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$6.00 -> $11.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

MediciNova (NASDAQ:MNOV) Earnings History and Estimates Chart

Earnings by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ MNOV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/29/2015Q3 2015($0.10)($0.06)ViewN/AView Earnings Details
7/30/2015Q2 2015($0.10)($0.09)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.14)$0.37 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.13)($0.14)$0.31 millionViewN/AView Earnings Details
11/8/2012Q312($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

MediciNova (NASDAQ:MNOV) Earnings Estimates

2017 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.09)($0.09)($0.09)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MediciNova (NASDAQ:MNOV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MediciNova (NASDAQ MNOV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 21.93%
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ MNOV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Yoshio IshizakaDirectorBuy5,000$5.17$25,850.00View SEC Filing  
5/15/2017Yutaka KobayashiDirectorBuy1,000$5.60$5,600.00View SEC Filing  
5/12/2017Yutaka KobayashiDirectorBuy24,000$5.62$134,880.00View SEC Filing  
9/15/2016Yutaka KobayashiDirectorBuy11,800$6.44$75,992.00View SEC Filing  
9/9/2016Yutaka KobayashiDirectorBuy10,000$6.67$66,700.00View SEC Filing  
7/5/2016Geoffrey ObrienVPSell3,300$8.00$26,400.00View SEC Filing  
12/10/2014Yutaka KobayashiDirectorBuy12,000$3.54$42,480.00View SEC Filing  
11/26/2014Yutaka KobayashiDirectorBuy10,000$3.07$30,700.00View SEC Filing  
11/20/2014Yutaka KobayashiDirectorBuy13,000$3.19$41,470.00View SEC Filing  
11/19/2014Yoshio IshizakaDirectorBuy5,000$2.86$14,300.00View SEC Filing  
9/11/2014Yutaka KobayashiDirectorBuy10,000$2.95$29,500.00View SEC Filing  
9/3/2014Yutaka KobayashiDirectorBuy15,000$2.66$39,900.00View SEC Filing  
12/12/2013Tatsuo IzumiDirectorSell71,270$2.10$149,667.00View SEC Filing  
11/18/2013Tatsuo IzumiDirectorBuy1,270$2.21$2,806.70View SEC Filing  
5/21/2013Arlene MorrisDirectorSell8,800$3.28$28,864.00View SEC Filing  
5/13/2013Tatsuo IzumiDirectorBuy158,730$3.15$499,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MediciNova (NASDAQ MNOV) News Headlines

Source:
DateHeadline
BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALSBRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
www.businessinsider.com - December 8 at 4:46 PM
MediciNova stock up more than 50% on positive trial resultsMediciNova stock up more than 50% on positive trial results
finance.yahoo.com - December 8 at 10:02 AM
Is MediciNova Inc (MNOV) Cheap And High Growth?Is MediciNova Inc (MNOV) Cheap And High Growth?
finance.yahoo.com - November 23 at 5:18 PM
MediciNova Appoints Hideki Nagao to its Board of DirectorsMediciNova Appoints Hideki Nagao to its Board of Directors
feeds.benzinga.com - November 10 at 2:55 AM
Is MediciNova Inc (MNOV) Undervalued?Is MediciNova Inc (MNOV) Undervalued?
finance.yahoo.com - November 8 at 8:53 PM
MNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MSMNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MS
finance.yahoo.com - November 1 at 6:21 AM
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability ProfileMediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile
finance.yahoo.com - October 31 at 6:28 AM
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability ProfileMediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile
finance.yahoo.com - October 31 at 6:28 AM
Medicinova (MNOV) Reports Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MSMedicinova (MNOV) Reports Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
www.streetinsider.com - October 27 at 8:00 AM
MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and TolerabilityMediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability
finance.yahoo.com - October 27 at 8:00 AM
MediciNova, Upcoming Phase II Data Presentation, Ibudilast ReviewMediciNova, Upcoming Phase II Data Presentation, Ibudilast Review
finance.yahoo.com - October 18 at 7:08 AM
MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine DependenceMediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
finance.yahoo.com - September 20 at 6:23 AM
MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New YorkMediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York
finance.yahoo.com - September 18 at 11:02 PM
MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, FranceMediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France
finance.yahoo.com - August 30 at 6:42 AM
Insider Buying: MediciNova, Inc. (MNOV) Director Acquires 5,000 Shares of StockInsider Buying: MediciNova, Inc. (MNOV) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - August 23 at 4:44 PM
MNOV: MN-166 Shows Activity in Preclinical Brain Cancer StudyMNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study
finance.yahoo.com - August 2 at 5:55 AM
Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)
www.streetinsider.com - April 26 at 6:43 PM
Mid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat ViewsMid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat Views
www.nasdaq.com - April 26 at 6:43 PM
MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017
www.nasdaq.com - April 10 at 10:25 AM
MediciNovas MN-166: Good Trial, But What About Generic Riluzole?MediciNova's MN-166: Good Trial, But What About Generic Riluzole?
seekingalpha.com - March 29 at 9:43 AM
MEDICINOVA INC Files SEC form 8-K, Regulation FD DisclosureMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:10 PM
MEDICINOVA INC Files SEC form 10-K, Annual ReportMEDICINOVA INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 14 at 8:09 PM
MediciNova Announces MN-166 (ibudilast) ALS...MediciNova Announces MN-166 (ibudilast) ALS...
www.benzinga.com - February 8 at 1:14 AM
Leading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disordersLeading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disorders
www.nasdaq.com - February 6 at 6:41 PM
Medicinova (MNOV) Positive MN-166 Data Published in NeuropsychopharmacologyMedicinova (MNOV) Positive MN-166 Data Published in Neuropsychopharmacology
www.streetinsider.com - January 23 at 6:55 PM
Medicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166Medicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166
www.streetinsider.com - December 21 at 9:40 AM
Medicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB ReviewMedicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB Review
www.streetinsider.com - December 20 at 12:30 PM
6:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H176:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H17
us.rd.yahoo.com - December 19 at 10:14 AM
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsMEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 5:56 PM
Medicinova (MNOV) Updates on FY16 OutlookMedicinova (MNOV) Updates on FY16 Outlook
www.streetinsider.com - October 26 at 6:14 PM
Medicinovas (MNOV) MN-166 Granted FDA Orphan Drug Designation as ALS TreatmentMedicinova's (MNOV) MN-166 Granted FDA Orphan Drug Designation as ALS Treatment
www.streetinsider.com - October 12 at 11:30 AM
MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsMEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - September 16 at 5:59 PM
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of FibrosisMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
www.nasdaq.com - July 26 at 6:33 PM
NVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015NVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015
www.rttnews.com - July 14 at 6:29 PM
Medicinova (MNOV) Announces Presentation of MN-166 Results in AUDMedicinova (MNOV) Announces Presentation of MN-166 Results in AUD
www.streetinsider.com - June 30 at 9:07 AM

SEC Filings

MediciNova (NASDAQ:MNOV) SEC Filings

DateFilerForm TypeView

Social Media

Financials

MediciNova (NASDAQ:MNOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MediciNova (NASDAQ MNOV) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.